Menu

More Vaccinations, Experimental Drugs as Potential Ebola Contacts Rise

The World Health Organization predicts the number of cases in Democratic Republic of Congo will rise up to 300 by July.  

May 30, 2018
Sukanya Charuchandra

 

ISTOCK, DK_PHOTOSThe ongoing Ebola outbreak in Democratic Republic of Congo has claimed 25 lives as of yesterday (May 29), reports Reuters, taking the total number of cases in the country to 54. This is DRC’s ninth tussle with the hemorrhagic fever since its first appearance in 1976.

The World Health Organization (WHO) is administering ring vaccinations to people who have had suspected contact, either directly or indirectly, with an Ebola patient. This means immunizing and monitoring all the individuals who have had potential contacts with patients, 906 people so far. Of those, more than 360 contacts vaccinated before Monday, reports The New York Times. The operation began in Mbandaka, a city of more than 1 million residents, last week. The rural town of Bikoro is the second site for vaccinations, which began this Monday (May 28).

A number of experimental drugs, including antibodies and antiviral options, are also available, according to Nature. WHO is awaiting the approval of DRC’s Ministry of Health to deploy them and begin trials, reports CNN.

A 2014-2016 episode of Ebola, which started in West Africa, racked up a death toll of more than 11,000 cases, and placed the WHO in a poor light. “We had no tools then, and by the time we had the vaccine ready to test, most of the cases had burned out,” Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, tells CNN. “We now have tools.”

“We are hearing about [the outbreak] and supporting a response to it much more quickly than the three-country outbreak in 2014-16,” says Anne Schuchat, principal deputy director of the US Centers for Disease Control and Prevention, to CNN.

A report on May 23 from ABC News of three escaped patients in Mbandaka sparked fears that they had spread the disease to the community. Two of them died and one is back under observation while WHO is trying to track anyone who might have come into contact with them. Health officials are “cautiously optimistic” about addressing the spread of Ebola, according to The Washington Post.

See “Experimental Ebola Vaccine to be Used in DRC Outbreak

See “Ebola Update: Funding, Vaccines, and More Deaths in DRC

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!